Full Text View
Tabular View
Study Results
Related Studies
Predictive Factors for Ovarian Stimulation Using a Fixed Daily Dose of 200 IU Recombinant FSH (Study 142003)(COMPLETED)(P05696) (Xpect)
This study has been completed.
Study NCT00778999   Information provided by Schering-Plough
First Received: October 23, 2008   Last Updated: October 2, 2009   History of Changes
Study Type: Interventional
Study Design: Randomized, Open Label, Active Control, Parallel Assignment
Condition: Infertility
Intervention: Drug: Desogen/Marvelon

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Desogen Oral Contraceptive Use of oral contraceptive pills prior to controlled ovarian stimulation
Non-Oral Contraceptive No use of oral contraceptive pills prior to controlled ovarian stimulation

Participant Flow:   Overall Study
  Desogen Oral Contraceptive Non-Oral Contraceptive
STARTED   223     219  
COMPLETED   195     185  
NOT COMPLETED   28     34  
      Discontinuation: no embryo transfer               14                 14  
      Did not receive recFSH               14                 20  



  Baseline Characteristics
  Hide Baseline Characteristics

Reporting Groups
  Description
Desogen Oral Contraceptive Use of oral contraceptive pills prior to controlled ovarian stimulation
Non-Oral Contraceptive No use of oral contraceptive pills prior to controlled ovarian stimulation

Baseline Measures
  Desogen Oral Contraceptive Non-Oral Contraceptive Total
Number of Participants  
[units: participants]
223 219 442
Age  
[units: participants]
     
<=18 years 0 0 0
Between 18 and 65 years 223 219 442
>=65 years 0 0 0
Gender  
[units: participants]
     
Female 223 219 442
Male 0 0 0



  Outcome Measures

1.  Primary:   Total Number of Oocytes   [ 12 weeks ]


  Serious Adverse Events
  Show Serious Adverse Events


  Other Adverse Events
  Show Other Adverse Events


  More Information
  Show More Information